Phase II results show ThGRF could be safe, effective treatment for lipodystrophy, says company
2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy and metabolic complications
Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir
2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Diabetes and HIV and HCV; aging/HIV and diabetes
2 May 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
FDA panel recommends approval of New-fill
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy regresses in three patients switched to atazanavir
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Rosiglitazone shows no benefit for lipoatrophy
2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Importance of dietary management in treating lipid disorders: soy diets may offer comparable effect as statins
3 February 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Human histology and persistence of various injectable filler substances for soft tissue augmentation
3 February 2004. Related: Lipodystrophy and metabolic complications.
Lower doses of d4T produce similar efficacy and reduced side effects
1 December 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Polylactic acid (New-gill) repairs facial wasting and improves quality of life
1 December 2003. Related: Lipodystrophy and metabolic complications.
Canadian study shows increased interventional cardiovascular procedures associated with HAART
1 November 2003. Related: Lipodystrophy and metabolic complications.
New guidelines for the evaluation and management of dyslipidaemia in HIV patients on HAART (2003)
1 October 2003. Related: Lipodystrophy and metabolic complications.
Treatments for lipoatrophy. Are there improvements? Are they noticeable?
1 October 2003. Related: Lipodystrophy and metabolic complications.
Rosiglitazone significantly increases triglyceride and cholesterol levels and does not improve HAART-associated lipoatrophy
1 October 2003. Related: Lipodystrophy and metabolic complications.
US approves and Europe rejects Serostim (recombinant growth hormone) for treatment of HIV-related wasting
1 October 2003. Related: Lipodystrophy and metabolic complications.
5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Underlying mechanisms: adipocytes and cytokines
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications, Basic science and immunology.
More mitochondrial DNA depletion
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
IMT and cardiovascular risk
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Reduced bone mineral density in HIV-positive women
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Rosiglitazone with insulin resistance
1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Additional benefits of exercise with metformin
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
1 September 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.
Facial fat loss – measuring and treatment
1 September 2003. Related: Conference reports, Treatment access, Lipodystrophy and metabolic complications.
Uridine treatment for mitochondrial toxicity
1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Breast enlargement in men and testosterone treatment
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Treatment interruption: a real choice
1 September 2003. Related: Conference reports, Treatment strategies, Lipodystrophy and metabolic complications.
HIV and heart disease: D:A:D prevalence rates show importance of accessing CVD risk in HIV patients
1 July 2003. Related: Lipodystrophy and metabolic complications.
HAART increases body fat at first; both d4T and AZT lead to subsequent fat loss
1 July 2003. Related: Lipodystrophy and metabolic complications.
Lipoatrophy improved by switching from d4T to abacavir
1 July 2003. Related: Lipodystrophy and metabolic complications.
Metabolic abnormalities in protease inhibitor-treated and protease naïve children
1 July 2003. Related: Paediatric care, Lipodystrophy and metabolic complications.
High levels of gout may be linked to HAART
1 June 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women
1 June 2003. Related: Lipodystrophy and metabolic complications.
Statins and fibrates both relatively effective for PI-induced hyperlipidemia
1 May 2003. Related: Lipodystrophy and metabolic complications.
Pioglitazone subjectively improves body shape abnormalities
1 May 2003. Related: Lipodystrophy and metabolic complications.
Conference has strong emphasis on women
1 April 2003. Related: Conference reports, Women's health, Lipodystrophy and metabolic complications, Cancer and HIV.
Approaches to treatment of lipodystrophy
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Surgery for buffalo hump shows variable results depending on method
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
HAART to HEART: cardiovascular risk in HIV
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Bone loss and fat loss are closely related in HIV patients on HAART
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Reduced testosterone levels in HIV-positive women
1 April 2003. Related: Women's health, Lipodystrophy and metabolic complications, Other news.
30-year study links vitamin A to risk of fracture in humans
1 March 2003. Related: Lipodystrophy and metabolic complications.
Bone turnover elevated in HIV-positive patients and linked to duration of HAART
1 March 2003. Related: Lipodystrophy and metabolic complications.
Protease inhibitors and cardiovascular outcomes in patients with HIV-1
1 March 2003. Related: Side effects, Lipodystrophy and metabolic complications.
HIV protease inhibitors promote atherosclerosis independent of dyslipidemia
1 March 2003. Related: Side effects, Lipodystrophy and metabolic complications.
HAART-associated hyperlipidaemia linked to low risk for cardiovascular disease (CVD)
1 March 2003. Related: Lipodystrophy and metabolic complications.
Patient on human growth hormone develops tumours with growth hormone receptors
1 March 2003. Related: Lipodystrophy and metabolic complications.
Review of trials shows testosterone increases lean body mass, and is most effective when given intramuscularly
1 March 2003. Related: Lipodystrophy and metabolic complications.
An overview of the conference
1 February 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.
Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.
Adipose tissue alterations develop early in antiretroviral therapy
1 February 2003. Related: Lipodystrophy and metabolic complications.
Perspectives on hormonal, mitochondrial and metabolic changes
1 December 2002. Related: Side effects, Lipodystrophy and metabolic complications.
IAS panel issues first guidelines for HIV and HIV drug-related metabolic complications (2002)
1 December 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy and adverse drug reaction data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
A range of treatments for facial lipoatrophy
13 November 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tamoxifen for male breast enlargement?
13 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Diet can help reduce lipid levels in people with HAART-related dyslipemia
13 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy syndrome and self-assessment of wellbeing and physical appearance in HIV-positive patients
1 November 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy
11 September 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Paracardial fat in HIV-infected patient resembles pericardial effusion
11 June 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Altered adipocyte differentiation associated with protease inhibitors and lipoatrophy
11 May 2002. Related: Side effects, Lipodystrophy and metabolic complications.
Study results shed light on cardiovascular risks: role of antiretrovirals and metabolism of lipids and sugars
10 April 2002. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.